The DOI matches its Crossref record; 303 of the 303 references it cites were found in a registry or an index.
Fluoxetine versus other types of pharmacotherapy for depression
Open accessAbstract
BACKGROUND: Depression is common in primary care and is associated with marked personal, social and economic morbidity, thus creating significant demands on service providers. The antidepressant fluoxetine has been studied in many randomised controlled trials (RCTs) in comparison with other conventional and unconventional antidepressants. However, these studies have produced conflicting findings.Other systematic reviews have considered selective serotonin reuptake inhibitor (SSRIs) as a group which limits the applicability of the indings for fluoxetine alone. Therefore, this review intends to provide specific and clinically useful information regarding the effects of fluoxetine for depression compared with tricyclics (TCAs), SSRIs, serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamineoxidase inhibitors (MAOIs) and newer agents, and other conventional and unconventional agents. OBJECTIVES: To assess the effects of fluoxetine in comparison with all other antidepressive agents for depression in adult individuals with unipolar major depressive disorder. SEARCH METHODS: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Review Group Controlled Trials Register (CCDANCTR)to 11May 2012. This register includes relevant RCTs from the Cochrane Central Register of Controlled Trials (CENTRAL) (all years),MEDLINE (1950 to date), EMBASE (1974 to date) and PsycINFO (1967 to date). No language restriction was applied. Reference lists of relevant papers and previous systematic reviews were handsearched. The pharmaceutical company marketing fluoxetine and experts in this field were contacted for supplemental data. SELECTION CRITERIA: All RCTs comparing fluoxetine with any other AD (including non-conventional agents such as hypericum) for patients with unipolar major depressive disorder (regardless of the diagnostic criteria used) were included. For trials that had a cross-over design only results from the first randomisation period were considered. DATA COLLECTION AND ANALYSIS: Data were independently extracted by two review authors using a standard form. Responders to treatment were calculated on an intention-to-treat basis: dropouts were always included in this analysis. When data on dropouts were carried forward and included in the efficacy evaluation, they were analysed according to the primary studies; when dropouts were excluded from any assessment in the primary studies, they were considered as treatment failures. Scores from continuous outcomes were analysed by including patients with a final assessment or with the last observation carried forward. Tolerability data were analysed by calculating the proportion of patients who failed to complete the study due to any causes and due to side effects or inefficacy. For dichotomous data, odds ratios (ORs) were calculated with 95% confidence intervals (CI) using the random-effects model. Continuous data were analysed using standardised mean differences (SMD) with 95% CI. MAIN RESULTS: A total of 171 studies were included in the analysis (24,868 participants). The included studies were undertaken between 1984 and 2012. Studies had homogenous characteristics in terms of design, intervention and outcome measures. The assessment of quality with the risk of bias tool revealed that the great majority of them failed to report methodological details, like the method of random sequence generation, the allocation concealment and blinding. Moreover, most of the included studies were sponsored by drug companies, so the potential for overestimation of treatment effect due to sponsorship bias should be considered in interpreting the results. Fluoxetine was as effective as the TCAs when considered as a group both on a dichotomous outcome (reduction of at least 50% on the Hamilton Depression Scale) (OR 0.97, 95% CI 0.77 to 1.22, 24 RCTs, 2124 participants) and a continuous outcome (mean scores at the end of the trial or change score on depression measures) (SMD 0.03, 95% CI -0.07 to 0.14, 50 RCTs, 3393 participants). On a dichotomousoutcome, fluoxetine was less effective than dothiepin or dosulepin (OR 2.13, 95% CI 1.08 to 4.20; number needed to treat (NNT) =6, 95% CI 3 to 50, 2 RCTs, 144 participants), sertraline (OR 1.37, 95% CI 1.08 to 1.74; NNT = 13, 95% CI 7 to 58, 6 RCTs, 1188 participants), mirtazapine (OR 1.46, 95% CI 1.04 to 2.04; NNT = 12, 95% CI 6 to 134, 4 RCTs, 600 participants) and venlafaxine(OR 1.29, 95% CI 1.10 to 1.51; NNT = 11, 95% CI 8 to 16, 12 RCTs, 3387 participants). On a continuous outcome, fluoxetine was more effective than ABT-200 (SMD -1.85, 95% CI -2.25 to -1.45, 1 RCT, 141 participants) and milnacipran (SMD -0.36, 95% CI-0.63 to -0.08, 2 RCTs, 213 participants); conversely, it was less effective than venlafaxine (SMD 0.10, 95% CI 0 to 0.19, 13 RCTs,3097 participants). Fluoxetine was better tolerated than TCAs considered as a group (total dropout OR 0.79, 95% CI 0.65 to 0.96;NNT = 20, 95% CI 13 to 48, 49 RCTs, 4194 participants) and
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–303 of 303
Demyttenaere, K., Albert, A., Mesters, P., Mesters, P., Dewé, W., Bruyckere, K. D., & Sangeleer, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0708 · Cited by 36
Mao, P., Tang, Y., Jiang, F., Shu, L., Gu, X., Li, M., Qian, M., Ma, C., Mitchell, P. B., & Cai, Z. (2006) · Depression and Anxiety · doi:10.1002/da.20222 · Cited by 36
Farabaugh, A. H., Mischoulon, D., D, M. F. M., Wu, S. L., Mascarini, A., Tossani, E., & Alpert, J. E. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200503000-00004 · Cited by 36
Trivedi, M. H., Dünner, D. L., Kornstein, S. G., Thase, M. E., Zajecka, J., Rothschild, A. J., Friedman, E. S., Shelton, R. C., Keller, M. B., Kocsis, J. H., et al. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.04.011 · Cited by 36
Reynaert, C., Janne, P., Vause, M., Zdanowicz, N., & Lejeune, D. (1995) · Psychopharmacology · doi:10.1007/bf02245861 · Cited by 35
Predictors of response to amine-specific antidepressants
Burns, R. A., Lock, T., Edwards, D. R. L., Katona, C., Harrison, D. A., Robertson, M. M., Nairac, B. L., & Abou‐Saleh, M. T. (1995) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00039-9 · Cited by 34
Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression
Figueira, M. L., Arriaga, F., Lara, E., Albuquerque, A. J., & Gamito, L. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)80184-3 · Cited by 33
Sackeïm, H. A., Roose, S. P., & Lavori, P. W. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.033 · Cited by 33
Moclobemide versus fluoxetine for a major depressive episode
Reynaert, C., Janne, P., Parent, M., Mirel, J., & Hazzen, L. (1995) · Psychopharmacology · doi:10.1007/bf02245838 · Cited by 32
Nielsen, B. M., Behnke, K., Arup, P., Christiansen, P. E., Geisler, A. E., Ipsen, E. Ø., Maach‐Møller, B., & Øhrberg, S. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03370.x · Cited by 32
A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness
Robertson, M. M., Abou‐Saleh, M. T., Harrison, D. A., Nairac, B. L., Edwards, D. R. L., Lock, T., Burns, R. A., & Katona, C. (1994) · Journal of Psychopharmacology · doi:10.1177/026988119400800205 · Cited by 31
Trajectories of improvement for six depression-related outcomes
Aikens, J. E., Kroenke, K., Nease, D. E., Klinkman, M. S., & Sen, A. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.10.003 · Cited by 31
Suri, R., Altshuler, L. L., Rasgon, N. L., Calcagno, J. L., Frye, M. A., Gitlin, M. J., Hwang, S., & Zuckerbrow-Miller, J. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1209 · Cited by 31
Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial
Beasley, C. M., Sayler, M. E., & Potvin, J. H. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00002 · Cited by 30
Tianeptine and fluoxetine in major depression: a 6‐week randomised double‐blind study
Novotný, V., & Faltus, F. (2002) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.411 · Cited by 30
Martinez, J. M., Katon, W. J., Greist, J. H., Kroenke, K., Thase, M. E., Meyers, A. L., Edwards, S. E., Marangell, L. B., Shoemaker, S., & Swindle, R. W. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32834ce11b · Cited by 30
Antidepressant Response and Plasma Concentrations of Fluoxetine
Preskorn, S., Silkey, B., Beber, J. H., & Dorey, C. (1991) · Annals of Clinical Psychiatry · doi:10.3109/10401239109147984 · Cited by 30
Bougerol, T., Scotto, J., Patris, M., Strub, N., Lemming, O. M., & Petersen, H. E. H. (1997) · Clinical Drug Investigation · doi:10.2165/00044011-199714020-00001 · Cited by 29
Timing of Clinical Improvement and Symptom Resolution in the Treatment of Major Depressive Disorder
Papakostas, G. I., Crawford, C. M., Scalia, M. J., & D, M. F. M. (2007) · Neuropsychobiology · doi:10.1159/000115779 · Cited by 27
Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial
Noguera, R., Altuna, R., Álvarez, E., Ayuso, J. L., Casais, L., & Udina, C. (1991) · Journal of Affective Disorders · doi:10.1016/0165-0327(91)90045-t · Cited by 27
Thase, M. E., Gelenberg, A. J., Kornstein, S. G., Kocsis, J. H., Trivedi, M. H., Ninan, P. T., Li, T., Pedersen, R., & Keller, M. B. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.07.009 · Cited by 27
Sheehan, D. V., Nemeroff, C. B., Thase, M. E., & Entsuah, R. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32831980f2 · Cited by 27
Guelfi, J., Bouhassira, M., Bonnett-Perrin, E., & Lancrenon, S. (1999) · PubMed · Cited by 27
Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitryptiline.
Altamura, A. C., Percudani, M., Guercetti, G., & INVERNIZZI, G. (1989) · PubMed · Cited by 27
Serrano‐Blanco, A., Gabarrón, E., García-Bayo, I., Soler-Vila, M., Caramés, E., Peñarrubia‐María, M. T., Pinto‐Meza, A., & Haro, J. M. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.11.014 · Cited by 25
Effects of fluoxetine on psychomotor performance, cognitive function and sleep in depressed patients
Kerr, J. S., Fairweather, D. B., & Hindrnarch, I. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300840-00025 · Cited by 25
Differential Effects of Trimipramine and Fluoxetine on Sleep in Geriatric Depression
Wolf, R., Dykierek, P., Gattaz, W. F., Maras, A., Kohnen, R., Dittmann, R. W., Geuppert, M., Riemann, D., & Berger, M. (2001) · Pharmacopsychiatry · doi:10.1055/s-2001-15183 · Cited by 25
Escitalopram in the Long-Term Treatment of Major Depressive Disorder in Elderly Patients
Kasper, S. F., Lemming, O. M., & de Swart, H. (2006) · Neuropsychobiology · doi:10.1159/000098650 · Cited by 25
Judd, F. K., Moore, K., Norman, T. R., Burrows, G. D., Gupta, R. K., & Parker, G. (1993) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679309072123 · Cited by 25
Why it is important to include unpublished data in systematic reviews
Trespidi, C., Barbui, C., & Cipriani, A. (2011) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796011000217 · Cited by 25
Self-citationMarchesi, C., Ceccherininelli, A., Rossi, A., & Maggini, C. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979331 · Cited by 24
Tryptophan and tyrosine availability and response to antidepressant treatment in major depression
Porter, R., Mulder, R., Joyce, P. R., & Luty, S. E. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.11.006 · Cited by 24
Amini, H., Aghayan, S., Jalili, S. A., Akhondzadeh, S., Yahyazadeh, O., & Pakravannejad, M. (2005) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2004.00585.x · Cited by 24
Lee, M.-S., Ham, B., Kee, B. S., Kim, J.-B., Yeon, B. K., Oh, K., Oh, B. H., Lee, C., Jung, H., Chee, I., et al. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59166 · Cited by 24
Fluoxetine versus clomipramine in major depressive disorders.
Ropert, R. (1989) · PubMed · Cited by 24
Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults.
Lapierre, Y. D., Joffe, R. T., McKenna, K., Bland, R., Kennedy, S. H., Ingram, P., Reesal, R. T., Rickhi, B., Beauclair, L., Chouinard, G., et al. (1997) · PubMed Central · Cited by 23
Gartlehner, G., Chapman, A. L., Strobelberger, M., & Thaler, K. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011895 · Cited by 23
Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression
Lönnqvist, J. K., Sihvo, S., Syvälahti, E. K. G., Sintonen, H., Kiviruusu, O. H., & Pitkanen, H. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09765.x · Cited by 23
Moclobemide Versus Fluoxetine in the Treatment of Inpatients With Major Depression
Gattaz, W. F., Vogel, P., Kick, H. A., & Kohnen, R. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199508001-00007 · Cited by 23
Murck, H., D, M. F. M., Alpert, J. E., Nierenberg, A. A., Mischoulon, D., Otto, M. W., Zajecka, J., Mannel, M., & Rosenbaum, J. F. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004717 · Cited by 22
Kornstein, S. G. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.5.737 · Cited by 22
Social reactions to Valium and Prozac: A cultural lag perspective of drug diffusion and adoption
Marshall, K. P., Georgievskava, Z., & Georgievsky, I. (2009) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2008.06.005 · Cited by 22
Moclobemide Versus Fluoxetine for Major Depressive Episodes
Geerts, S., Bruynooghe, F., Cuyper, H. D., Demeulemeester, F., & Haazen, L. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199417001-00007 · Cited by 22
Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders.
Poelinger, W., & Haber, H. L. (1989) · PubMed · Cited by 22
Pia, S. L., Giorgio, D., Ciriello, R., Sannino, A., Simone, L. D., Paoletti, C., & Colonna, C. V. (1992) · Current Therapeutic Research · doi:10.1016/s0011-393x(05)80057-8 · Cited by 21
De Ronchi, D., Rucci, P., Lodi, M., Ravaglia, G., Forti, P., & Volterra, V. (1998) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(98)80021-6 · Cited by 20
Friede, M., Zepelin, H. H., & Freudenstein, J. (2001) · Pharmacopsychiatry · doi:10.1055/s-2001-15459 · Cited by 20
Two year follow-up of atypical depression
Zubieta, J. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)00035-1 · Cited by 20
Moclobemide versus fluoxetine for double depression: A randomized double-blind study
Duarte, A., Mikkelsen, H., & Delini‐Stula, A. (1996) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(96)00030-1 · Cited by 20
Taner, E., Demir, E., & Çoşar, B. (2006) · Advances in Therapy · doi:10.1007/bf02850218 · Cited by 20
Akhondzadeh, S., Faraji, H., Sadeghi, M., Afkham, K., Fakhrzadeh, H., & Kamalipour, A. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.0269-4727.2003.00505.x · Cited by 20
Kornstein, S. G., Kocsis, J. H., Ahmed, S., Thase, M. E., Friedman, E. S., Dunlop, B. W., Yan, B., Pedersen, R., Ninan, P. T., Li, T., et al. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328314e2cb · Cited by 19
Fluoxetine in endogenous depression and melancholia versus clomipramine.
Ginestet, D. (1989) · PubMed · Cited by 19
A Double-blind Multi-centre Trial of Fluoxetine and Dothiepin in Major Depressive Illness
SOUTH WALES ANTIDEPRESSANT DRUG TRIAL GROUP (1988) · International Clinical Psychopharmacology · doi:10.1097/00004850-198801000-00006 · Cited by 19
A double-blind study of fluoxetine and imipramine in major depression.
Bressa, G. M., Brugnoli, R., & Pancheri, P. (1989) · PubMed · Cited by 18
Fluoxetine Versus Trimipramine in the Treatment of Depression in Geriatric Patients
Wehmeier, P. M., Kluge, M., Maras, A., Riemann, D. W., Berger, M., Kohnen, R., Dittmann, R. W., & Gattaz, W. F. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-837765 · Cited by 18
Hosák, L., Tůma, I., Hanuš, H., & Straka, L. (2000) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2019.127 · Cited by 18
Comparison of fluoxetine and desipramine in depressed outpatients
Remick, R. A., Claman, J., Reesal, R. T., Gibson, R. E., Agbayewa, M. O., Lam, R. W. M., & Keller, F.-E. (1993) · Current Therapeutic Research · doi:10.1016/s0011-393x(05)80653-8 · Cited by 17
Kornstein, S. G. (2006) · CNS Spectrums · doi:10.1017/s1092852900015236 · Cited by 16
A comparative trial of a new antidepressant, fluoxetine.
Levine, S., Deo, R., & Mahadevan, K. (1989) · PubMed · Cited by 16
Tamminen, T., & Vv, L. (1989) · PubMed · Cited by 16
Loeb, C., Albano, C., & Gandolfo, C. (1989) · PubMed · Cited by 16
Orosomucoid influences the response to antidepressants in major depressive disorder
Harley, J., Roberts, R. L., Joyce, P. R., Mulder, R., Luty, S. E., Frampton, C., & Kennedy, M. A. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109105101 · Cited by 15
Hunter, A. M., Ravikumar, S., Cook, I. A., & Leuchter, A. F. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01305.x · Cited by 15
[Double-blind study of mianserin and fluoxetine in ambulatory therapy of depressed patients].
Besançon, G., Cousin, R., Guitton, B., & Lavergne, F. (1993) · PubMed · Cited by 14
The efficacy and acceptability of amineptine versus fluoxetine in major depression
Jean Dalery, A., Rochai, C., Peyron, E., & Bernard, G. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199707003-00006 · Cited by 14
The efficacy of fluoxetine versus maprotiline in depressed patients and by dose
Kuha, S., Mehtonen, O. ‐., Henttonen, A., & Naarala, M. (1991) · Nordic Journal of Psychiatry · doi:10.3109/08039489109103274 · Cited by 14
Ballenger, J. C. (2009) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)79087-x · Cited by 14
Manna, V., Martucci, N., & AGNOLI, A. (1989) · PubMed · Cited by 14
Bitran, S., Farabaugh, A. H., Ameral, V., LaRocca, R. A., Clain, A. J., D, M. F. M., & Mischoulon, D. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328343ba08 · Cited by 13
Fairweather, D. B., Stanley, N., Yoon, J. S., & Hindmarch, I. (1999) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199907)14:5<325::aid-hup102>3.0.co;2-3 · Cited by 13
Placebo‐controlled study of ABT‐200 versus fluoxetine in the treatment of major depressive disorder
Sramek, J. J., Kashkin, K. B., Jasinsky, O., Kardatzke, D. R., Kennedy, S., & Cutler, N. R. (1995) · Depression · doi:10.1002/depr.3050030407 · Cited by 13
Bias in the evaluation of antidepressants
Hotopf, M. H., & Barbui, C. (2005) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00006242 · Cited by 13
Self-citationFluoxetine versus amineptine in the treatment of outpatients with major depressive disorders.
Ferreri, M. (1989) · PubMed · Cited by 13
Pakesch, G., & Dossenbach, M. R. K. (1991) · PubMed · Cited by 12
Fluoxetine versus nomifensine in outpatients with neurotic or reactive depressive disorder.
Taneri, Z., & Köhler, R. (1989) · PubMed · Cited by 12
Shirazi, H. R. G., Hashemi, S. N., Mohamadi, A., Gh, Z.-B., & Malekzadeh, M. (2012) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s23831 · Cited by 11
Raman, G., Kitsios, G. D., Moorthy, D., Hadar, N., Dahabreh, I. J., O’Donnell, T. F., Thaler, D. E., Feldmann, E. G., & Lau, J. T. F. (2012) · Cited by 11
A double-blind comparison of nefazodone and fluoxetine in the treatment of depressed outpatients
Berlanga, C., Arechavaleta, B., Heinze, G., Campillo, C., Torres, M., Caballero, A., Apiquián, R., & Castelli, P. (1997) · Salud Mental · Cited by 10
A six month sertraline fluoxetine comparative study in depressed outpatients: Outcome and costs
Bisserbe, J. C., Boyer, P., Souêtre, E., et al. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)87960-0 · Cited by 10
Amisulpride versus fluoxetine in dysthymia: preliminary results of a double-blind comparative study
Smeraldi, E., Haefele, E., Crespi, G., Casadei, G., Biondi, F., & Vigorelli, E. (1996) · European Psychiatry · doi:10.1016/0924-9338(96)85189-3 · Cited by 9
NOREPINEPHRINE OUTPUT AND METABOLISM IN DEPRESSED PATIENTS DURING ANTIDEPRESSANT TREATMENTS
Schildkraut, J. J., Schatzberg, A. F., Samson, J. A., ROSENBAUM, A., & Bowden, C. L. (1992) · Clinical Neuropharmacology · doi:10.1097/00002826-199201001-00167 · Cited by 8
Huang, L. J. (2009) · Zhongguo xin yao zazhi · Cited by 7
Freemantle, N., & Mason, J. M. (2000) · PharmacoEconomics · doi:10.2165/00019053-200017040-00001 · Cited by 6
Nahler, G. (2009) · Dictionary of Pharmaceutical Medicine · doi:10.1007/978-3-211-89836-9_417 · Cited by 6
Suleman, M.-I., Sebit, M. B., Acuda, S. W., & Siziya, S. (1997) · Central African Journal of Medicine · Cited by 6
Cochrane reviews impact on mental health policy and practice
Barbui, C., & Tansella, M. (2011) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796011000394 · Cited by 5
Self-citationA multicentre open trial of fluoxetine in depressed out-patients in Belgium.
Brasseur, R. (1989) · PubMed · Cited by 5
P-2-116 SSRIs in the treatment of depressed out patients aged 70 years and older
NEWHOUSE, P. A., Finkel, S. I., & Richter, E. M. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)90481-r · Cited by 4
Double blind randomized comparative study of sertraline and fluoxetine in depressive outpatients
Sechter, D., & Troy, S. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)88002-x · Cited by 4
Sechter, D., Troy, S., & Rioux, P. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)87877-1 · Cited by 3
Paton, C. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1016 · Cited by 3
Fluoxetine and ammitriptyline in the treatment of major depression with associated anxiety
Versiani, M., Plewes, J. M., Ontiveiros, A., Mazzotti, G., Ospina, J. M., Dávila, J., Mata, S., Pacheco, A., Tamura, R., Palacios, M., et al. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)80266-6 · Cited by 2
Comparing the Efficacy and Safety of Fluoxetine and Venlafaxine in Outpatient Depression
Michelson, D. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0512e · Cited by 2
Scapicchio, P. L. (2008) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology · Cited by 2
Li-q, Y., & 姚立旗 (2005) · Chin J Psychiatry · doi:10.3760/j:issn:1006-7884.2005.03.009 · Cited by 2
Armitage, R., Yonkers, K. A., Rush, A. J., Cole, D., & Novak, K. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)90437-i · Cited by 1
Onset of action in the pharmacologic treatment of dysthymia
Jorit, M. C., Cesana, B. M., & Casadeit, G. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)80144-2 · Cited by 1
Fu-gang, S. (2006) · Medical Journal of Chinese People's Health · Cited by 1
A Comparative Study of Citalopram and Fluoxetine in the Treatment of Senile Depressive Disorders
Zhao, H. (2005) · Zhongguo xinli weisheng zazhi · Cited by 1
Clinical differences in response to mianserin and fluoxetine in depressive patients
Lavergne, F., Berlin, I., Payan, C., & Besançon, G. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)87878-3 · Cited by 1
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
(2000) · doi:10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h
(2000) · doi:10.1002/1099-1077(200010)15:7<529::aid-hup232>3.0.co;2-g
Cited by
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Self-citationCross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud, A. M., Zotti, R. J., Shehzad, Z., Gueorguieva, R., Johnson, M. K., Trivedi, M. H., Cannon, T. D., Krystal, J. H., & Corlett, P. R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00471-x · Cited by 676
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Bauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., WFSBP Task Force on Unipolar Depres, Bauer, M., Bschor, T., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 477
Metadata
- Authors
- Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2013-07-17
- Volume
- 2013
- Issue
- 7
- Pages
- CD004185-CD004185
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1868235462
- Cited by
- 252
- References
- 303
- FWCI
- 13.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.